title: Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
abstract: Secondary malignancies are an important cause of morbidity and mortality in childhood cancer survivors. Salivary gland tumors account for about 6% of the second cancers. The majority of these are mucoepidermoid carcinomas (MEC) of the parotid gland. We report the clinical and pathological features of a rarer histological type, acinic cell carcinoma (ACC), in a childhood acute lymphoblastic leukemia (ALL) survivor. The behavior of secondary ACC appears similar to primary tumor and similar treatment may be adopted. Early recognition and complete resection is important for achieving a good outcome. Careful monitoring for recurrence or a third malignancy is needed.
authors.affiliation: Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China. cheukkld@hkucc.hku.hk
authors.forename: Daniel Ka Leung
authors.initials: DK
authors.lastname: Cheuk
authors.forename: Tony Wai Hung
authors.initials: TW
authors.lastname: Shek
authors.forename: Godfrey Chi Fung
authors.initials: GC
authors.lastname: Chan
authors.forename: Yu Lung
authors.initials: YL
authors.lastname: Lau
authors.forename: Shau Yin
authors.initials: SY
authors.lastname: Ha
authors.forename: Alan Kwok Shing
authors.initials: AK
authors.lastname: Chiang
mesh_terms: D006607:Adenoma, Sweat Gland / Q000209:etiology / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D018267:Carcinoma, Acinar Cell / Q000139:chemically induced / Q000209:etiology* / Q000532:radiotherapy / Q000601:surgery; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009381:Neoplasms, Radiation-Induced / Q000209:etiology* / Q000532:radiotherapy / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000209:etiology* / Q000532:radiotherapy / Q000601:surgery; D010307:Parotid Neoplasms / Q000139:chemically induced / Q000209:etiology* / Q000532:radiotherapy / Q000601:surgery; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D012074:Remission Induction; D017741:Survivors; D013544:Sweat Gland Neoplasms / Q000209:etiology / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014916:Whole-Body Irradiation / Q000009:adverse effects*
chemical_list: D003561:Cytarabine; D015251:Epirubicin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin